Loading
Xilio Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Shannon James Samuel, was filed 30 Mar 2026.
Xilio Therapeutics, Inc.: what insiders have been doing
Xilio Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 5 insiders have disclosed 7 filings since 23 October 2025.
Open-market activity splits into 1 purchase totalling €38k and 2 sales totalling €4,848; 1 insider sit on the buying side and 2 insiders on the selling side. On balance, insiders were net buyers of €33k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €38k from Shannon James Samuel, disclosed on 30 March 2026. On the buying side, the filings list 1 senior executive among the declarants.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 7 filings, this issuer sits below that mark. The full history, which starts in 2021, counts 15 purchases against 10 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 43.8 m USD and net income at -35.0 m USD.
The latest purchase dates back some time: it was published 208 days ago, on 30 March 2026. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
63
Thresholds
n/a
Buy Volume
€25M
15 ops. · all time
Sell Volume
€17,043
10 ops. · all time
Who traded when
BuySaleJames Samuel Shannon3 buys
Christopher James Frankenfield2 sales
Kevin M. Brennan2 sales
Gilead Sciences, Inc.1 buy
Rene Russo1 buy
Since the insiders bought
- +10.2%Entry US$8.41 · Close at T+90 US$9.27
- -7.3%Entry US$9.65 · Close at T+365 US$8.94
- -48.3%Entry US$17.92 · Close at T+365 US$9.27
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,988 of 26,248 companies
6.9
score / 100
Value11
Quality3
FCF yld-10%
Earn yld-64%
EV/EBITDA·
ROE-55%
Gross mgn·
Net mgn-80%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.33
Analyst consensus
1 analystsUS$20.00Target US$20.00(+140%)US$20.00
Income statement
RevenueUS$43.8M
EBITDA-US$40.4M-92% margin
Net income-US$35M-34.1% margin
Valuation
P/Book1.1x
Beta-0.12
Balance sheet & cash
Market capUS$54.8M
Total debtUS$7M
Free Cash Flow-US$5.5M
Debt / Equity9%
Profitability & ownership
ROE-55.0%
ROA-13.6%
% insiders26.0%
% institutions49.4%
Last declaration on 30 March 2026
Declarations63 total
5,000 shares@ US$8.7958.7% of flowCommon StockSEC:0001193125-26-131745:0
Canonical exit: 24 Jun 2026 (T+90)
7,030 shares@ US$0.643236.8% of flowCommon StockSEC:0001193125-26-002517:1
1,826 shares@ US$0.643236.8% of flowCommon StockSEC:0001193125-26-002518:1
16,625 sharesCommon StockSEC:0001193125-26-002520:0
5,000 sharesCommon StockSEC:0001193125-26-002518:0
19,375 sharesCommon StockSEC:0001193125-26-002517:0
44,250 sharesCommon StockSEC:0001193125-26-002512:0
25,000 shares@ US$0.688618.8% of flowCommon StockSEC:0001415889-25-017705:1
Canonical exit: 15 Sept 2025 (T+90)
45,000 shares@ US$0.68641.3% of flowCommon StockSEC:0001415889-25-017705:0
Canonical exit: 14 Sept 2025 (T+90)
36,289 shares@ US$0.6801100.0% of flowCommon StockSEC:0001415889-25-017704:0
Canonical exit: 14 Sept 2025 (T+90)
6,954 shares@ US$0.983763.2% of flowCommon stockSEC:0001415889-25-000407:1
1,803 shares@ US$0.983763.2% of flowCommon stockSEC:0001415889-25-000404:1
16,625 sharesCommon StockSEC:0001415889-25-000406:0
5,000 sharesCommon StockSEC:0001415889-25-000404:0
44,250 sharesCommon StockSEC:0001415889-25-000405:0
19,375 sharesCommon StockSEC:0001415889-25-000407:0
1,759,978 shares@ US$1.0483.6% of flowCommon StockSEC:0001062993-24-020910:0
Canonical exit: 18 Mar 2025 (T+90)
485,250 shares@ US$0.7616.4% of flowCommon StockSEC:0001062993-24-008004:0
Canonical exit: 1 Jul 2024 (T+90)
267 shares@ US$0.640.0% of flowCommon StockSEC:0001209191-24-003031:1
733 shares@ US$0.6411.7% of flowCommon StockSEC:0001209191-24-003031:0
1,566 shares@ US$0.8733.4% of flowCommon StockSEC:0001209191-24-001655:0
569 shares@ US$0.8712.1% of flowCommon StockSEC:0001209191-24-001655:1
1,540 shares@ US$0.8331.3% of flowCommon StockSEC:0001209191-24-001655:2
560 shares@ US$0.8311.4% of flowCommon StockSEC:0001209191-24-001655:3
4,011 shares@ US$9.84429.6% of flowCommon StockSEC:0000899243-21-047829:1
Canonical exit: 9 Mar 2022 (T+90)
25 of 63 declarations
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biotechnology company based in the United States, with headquarters in Waltham, Massachusetts. For European investors, Xilio is best understood as a small-cap U.S. biotech focused on next-generation immuno-oncology, specifically masked or tumor-activated therapies designed to improve the therapeutic window of cancer treatments. The company was built around a proprietary masking platform intended to keep drug activity concentrated in the tumor microenvironment, thereby reducing systemic exposure and potentially improving tolerability. Xilio trades on the NASDAQ market in the United States, which places it squarely in the group of U.S. biotech names that are typically driven by clinical catalysts, partnership updates, and financing needs. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-pipeline-and-business-updates-11/?utm_source=openai))
Xilio’s business model combines internal drug development with collaboration and licensing agreements that can generate milestone payments and other non-dilutive funding. The company’s core strategic asset is its clinically validated masking technology, which it uses to design immuno-oncology therapies with the goal of achieving stronger tumor selectivity than conventional approaches. Its current pipeline includes XTX501, a masked bispecific PD-1 / IL-2 program that management has described as a potential backbone therapy for combination regimens across solid tumors, as well as XTX601, a masked T-cell engager targeting CLDN18.2. Xilio is also advancing additional masked programs, giving it a platform story rather than dependence on a single asset. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-reports-first-quarter-2026-financial-results?utm_source=openai))
Read moreShow less
Competitively, Xilio occupies an attractive but highly risky niche. Its potential edge lies in its ability to mask active agents until they reach the tumor, which could matter in solid tumors where toxicity has historically limited the utility of cytokines and T-cell engagers. At the same time, the company competes with larger biopharma groups and better-capitalized biotech peers pursuing bispecific antibodies, engineered cytokines, and T-cell engager platforms. Xilio’s valuation therefore depends heavily on early clinical validation, IND-enabling progress, regulatory execution, and the ability to secure collaborations or additional capital. Like many clinical-stage biotech companies, it does not yet have a commercial product base, so the investment case is still primarily binary and event-driven. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-pipeline-and-business-updates-11/?utm_source=openai))
Recent highlights include first-quarter 2026 financial results, new preclinical data presented at AACR 2026 for XTX601, and continued advancement of XTX501 toward an expected IND submission in 2026. The company also reported pipeline and business updates in early 2026 and had previously closed a $50 million public offering in 2025 to support development and general corporate purposes. Overall, Xilio remains a high-risk, high-catalyst U.S. biotech story: scientifically differentiated, still pre-commercial, and highly dependent on execution milestones over the next several quarters. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-reports-first-quarter-2026-financial-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
